EMVS celebrates 1 year of successful operation across Europe

The EMVS protects patients from the risk of falsified medicines through an end-to-end verification of medicinal packs. Prescription medicines dispensed in Europe must bear safety features and be verified for their authenticity via the EMVS before they are given to patients.

The EMVS implements the Falsified Medicines Directive 2011/62/EU (FMD) which requires the placing of two safety features on the packaging of some (mainly prescription) medicines for human use for the purpose of their identification and verification of their authenticity via an interoperable digital system across the whole EU.

The EMVS is also a unique collaboration model where the stakeholders of the pharmaceutical supply chain connect 28 national systems, operated and managed by the National Medicines Verification Organisations, to a European Hub, operated and managed by EMVO.

Adrian van Den Hoven, President of EMVO, comments: “The EMVS is a monumental project, connecting 28 EEA countries and more than 2,500 Marketing Authorisation Holders (MAHs) and over 100,000 wholesalers, pharmacists and hospitals to the system. The first year of the EMVS has seen substantial collaboration between all stakeholders in the pharmaceutical supply chain to get this project up and running successfully and this will continue as we ramp up the system over the next few years”.

Andreas Walter, General Manager of EMVO, states: “The teams of EMVO and of the National Medicines Verification Organisations have worked tirelessly over the past 12 months to improve patient safety through the establishment of a successful system. Our organisation will continue to be the central point for the EMVS, working at a European level with EMVO’s stakeholders and with each National Medicines Verification Organisation to fulfil the verification mission entrusted to us by regulatory authorities.”

More information: EMVO Website: www.emvo-medicines.eu